Abstract
Monoclonal antibody-mediated cancer therapy has evolved through a challenging chain of problems and solutions. The very limited therapeutic success obtained with unarmed monoclonal antibodies has increased the interest in different antibody-based targeting strategies, and numerous preclinical and even clinical studies with immunoconjugates have now been conducted. We comment here on the messages implicit in a recent report on a doxorubicin-anti-carcinoma antibody conjugate and from several other studies.
| Original language | English |
|---|---|
| Pages (from-to) | 698-701 |
| Number of pages | 4 |
| Journal | Annals of Oncology |
| Volume | 5 |
| Issue number | 8 |
| Publication status | Published - 1994 |
Keywords
- Immunoconjugates
- Monoclonal antibodies
- Preclinical models
ASJC Scopus subject areas
- Cancer Research
- Statistics, Probability and Uncertainty
- Applied Mathematics
- Hematology
- Oncology
- Public Health, Environmental and Occupational Health
- Neuropsychology and Physiological Psychology